Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal
Insilico Medicine and TaiGen Biotechnology (including its Beijing subsidiary TaiGen Biopharmaceuticals) announced an exclusive pipeline...
Insilico Medicine
Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance
Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...
China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration
Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...
Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...
Insilico Medicine Files for IPO to Leverage AI in Drug Discovery
China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...
Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...
Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...
Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease
China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt...
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge...
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...